Poma Eric E reported grant involving 32,000 derivative units of Calidi Biotherapeutics, Inc. on Aug 17, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Chief Executive Officer
Chief Executive Officer
Filed Aug 19, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
—Shares × reported price
Shares traded
32,000Stock Options (right to buy)
Price per share
Price unknownReported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
32,000Direct
Trade date
Aug 17, 2026Grant
Filed
Aug 19, 2026, 7:00 PM ET2-day reporting delay
Accession
0001493152-26-039287Code A · Transaction 12142
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

Filing warnings

Notes recorded with this filing
1 warning
missing priceThe filing did not provide a usable price per share.

CLDI price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
CLDI · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago −92%1w ago +18%1d ago +15%
Returns since7d −2.2%30d −20%90d180d1y

Footnotes in full

F1: Pursuant to the Issuer's 2023 Equity Incentive Plan (the "2023 Plan"), on August 17, 2026 (the "Grant Date"), the Reporting Person was granted 32,000 incentive stock options (the "Options") at an exercise price of $1.36, which is equal to the closing price of the Issuer's common stock on the Grant Date. 25% of the options will vest upon the one (1) year anniversary of 08/17/2026, and the remaining 75% of the options will vest in 1/36th installments on a monthly basis, subject to the Reporting Person's continued service to the Issuer. The Options were granted in a transaction exempt under Rule 16b-3 to the Reporting Person. F2: Does not include the incentive stock options previously granted to the Reporting Person.